

ABBOTT LABORATORIES  
Form 8-K  
August 03, 2007

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

July 31, 2007  
Date of Report (Date of earliest event reported)

## ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

**Illinois**  
(State or other Jurisdiction of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(I.R.S. Employer  
Identification No.)

---

**100 Abbott Park Road**  
**Abbott Park, Illinois 60064-6400**  
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(847) 937-6100**

**Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Abbott today announced that Richard A. Gonzalez, President and Chief Operating Officer and a member of Abbott's Board of Directors, plans to retire from the company after 30 years of service, effective September 30, 2007.

Accordingly, Abbott's medical devices, pharmaceuticals, nutritionals and diagnostics businesses will report directly to Miles D. White, Chairman and Chief Executive Officer.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 3, 2007

**Abbott Laboratories**

By: /s/ Thomas C. Freyman  
Thomas C. Freyman  
Executive Vice President, Finance  
and Chief Financial Officer